NovImmune SA Initiates Phase I Clinical Study With First-in-Class Anti-TLR4 Monoclonal Antibody

GENEVA--(BUSINESS WIRE)--NovImmune SA initiated dosing in a Phase I clinical trial of NI-0101, a monoclonal antibody drug candidate targeting toll-like receptor-4 (TLR4). NI-0101 was discovered and developed by NovImmune, and has broad potential applications. NovImmune has demonstrated efficacy of TLR4 blockade in a range of preclinical models of arthritis, respiratory inflammation, organ injury, as well as other autoimmune and inflammatory conditions. The first-in-human study in healthy volunteers will generate information for pharmacokinetic and pharmacodynamic properties as well as safety and tolerability data. NovImmune’s Chief Medical Officer, Cristina de Min, said, "Data generated during this Phase I program, coupled with the information from pre-clinical experiments in relevant animal models for human diseases, will build a solid foundation to advance NI-0101 into Phase II studies.”